Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, May 29 2019

Full Issue

Can A Side Effect Of A 'Life-Saving' Drug Be Worse Than Possibly Facing Cancer?

Patients who are undergoing immunotherapy are developing a disease akin to type 1 diabetes. “If I knew then, when I opted for the clinical trial, what type 1 diabetes entailed, I would never have gone for the immunotherapy. Never. I would have taken the chance of the cancer coming back,” said Jaime Vidal, 79, a retired mailman from San Bruno, Calif. In other pharmaceutical news: accelerated approvals for cancer drugs, troubling manufacturing problems and the right-to-try bill.

Stat: Powerful New Cancer Drugs Can Trigger Diabetes — And No One Knows Why

Roughly 1% of patients receiving immunotherapy drugs experience the same irreversible side effect. Making matters worse, oncologists have little clue why. ...On Wednesday, the Parker Institute for Cancer Immunotherapy, JDRF (formerly called the Juvenile Diabetes Research Foundation), and the Helmsley Charitable Trust announced they are joining forces to launch a $10 million, three-year research initiative designed to identify the root causes of drug-induced diabetes among cancer patients. (Dolgin, 5/29)

NPR: FDA's Accelerated Approvals For Cancer Drugs At Odds With Many Later Studies

Cancer drugs that speed onto the market based on encouraging preliminary studies often don't show clear benefits when more careful follow-up trials are done, according to research published Tuesday. These cancer drugs are granted accelerated approval to give patients faster access to the treatments and to allow drug companies to reap the economic rewards sooner. As a condition of this process, the Food and Drug Administration requires drug companies to conduct more research, to confirm whether the medications actually work and are safe. (Harris, 5/28)

Stat: Drug Maker Tells FDA A Dancing Holiday Was To Blame For Infractions

During an inspection of a Centurion Laboratories facility in India last October, a Food and Drug Administration investigator noticed a variety of troubling manufacturing problems. These included a failure to follow written procedures for cleaning and maintaining equipment. Specifically, the investigator noticed equipment in one room that was marked as cleaned actually had “visible product build-up” and an air filter was damaged with multiple holes. This mattered to the FDA because the equipment was used to make drugs shipped to the U.S. (Silverman, 5/28)

Cincinnati Enquirer: A Year After Federal Right-To-Try Bill, Paul Rinderknecht Lives In Hope

Getting sick turned Paul Rinderknecht of Springfield Township into a political activist for terminal patients who want more access to experimental drugs. A year ago, President Donald Trump signed the right-to-try law, and Rinderknecht celebrated. Yet the law has not helped him or thousands of other Americans who hoped for relief from dire conditions such as brain cancer and, in Rinderknecht’s case, the progressive paralysis known as Lou Gehrig’s disease. (Saker, 5/27)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF